CTOs on the Move


 
Ocugen Inc.is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Ocugen raised $23M on 02/10/2021
Ocugen raised $100M on 04/26/2021

Similar Companies

Crescent City Surgical Centre

Crescent City Surgical Centre is a Metairie, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

M3 Biotechnology

M3 is a biopharmaceutical company focused on development of therapeutics to address Alzheimer`s, Parkinson`s and Neurodegeneration.

Aduro Biotech

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro`s technology platforms, which are designed to harness the body`s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro`s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro`s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro`s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms.

National Institutes of Health

The National Institutes of Health (NIH) is the largest biomedical research agency in the world, conducting research in its own laboratories, supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research ins...

Casma Therapeutics

New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today. Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.